In a report released today, Joseph Catanzaro from Piper Sandler maintained a Hold rating on Iovance Biotherapeutics (IOVA – Research Report), with a price target of $7.50. The company’s shares ...

In a report released today, Asthika Goonewardene from Truist Financial assigned a Buy rating to Iovance Biotherapeutics (IOVA – Research Report). The company’s shares closed yesterday at $6.07.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) shares hit a new 52-week low during trading on Monday after Piper Sandler lowered their price target on the stock from $10.00 to $7.50.

SG Americas Securities LLC purchased a new position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) in the 4th quarter, Holdings Channel.com reports.The fund purchased ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Iovance Biotherapeutics (NASDAQ: IOVA), a small-cap biotech company, has an innovative approach to treating cancer that relies on harnessing patients' cancer-fighting capabilities. Though the ...

It was about a year ago that shares of Iovance Biotherapeutics (NASDAQ: IOVA) began to take off. The stock soared on news of approval from the Food and Drug Administration for Amtagvi (lifileucel ...

In this article, we are going to take a look at where Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) stands against other Billionaire Joseph Edelman’s long-term stock picks. Joseph Edelman is a ...

Stifel maintains Buy on Iovance stock with $21 target On Monday, Stifel analysts maintained a Buy rating on Iovance Biotherapeutics (NASDAQ:IOVA) with a steady price target of $21.00. According to ...